biotech peptides FAQ

Recombinant expression is the only cost-viable route at gram scale unless the peptide is shorter than 15 amino acids. Budget $8,000–$15,000 for a custom recombinant production run including expression optimization, fermentation, purification, and endotoxin removal to <1 EU/mg. Chemical synthesis at that scale costs $40,000–$80,000 depending on sequence complexity. The purity trade-off (85-92% recombinant vs 95-98% chemical) is acceptable for PK studies and toxicity screens where the biological effect is robust, but problematic for mechanistic studies requiring precise molar dosing.

Naturally derived sources or mammalian cell expression systems are your only options. For glycosylated peptides, Chinese hamster ovary (CHO) cell expression produces native N-glycosylation patterns, but production timelines extend to 12-16 weeks and cost increases 3-5× over bacterial recombinant routes. Alternatively, enzymatic glycosylation of chemically synthesized peptide backbones using glycosyltransferases provides site-specific modification with defined glycan structures. A middle-ground approach that several specialty suppliers now offer for peptides under 30 residues.

Request synthesis feasibility analysis from suppliers offering modified coupling or microwave-assisted routes before concluding the sequence is unsynthesizable. Peptides containing Pro-Pro-Gly motifs, extended polyArg stretches, or highly hydrophobic C-termini often fail on standard platforms but succeed with alternative activation chemistry. If chemical synthesis remains infeasible, recombinant expression becomes the fallback. But you'll need sequence optimization (codon usage, fusion tag selection) and refolding protocol development, which adds 4-8 weeks to delivery time.

Evaluate based on the application's tolerance for impurities and the consequences of batch-to-batch variability. For cell culture assays with robust readouts (e.g., viability, proliferation), peptides with 90–95% purity from either synthesis method are generally acceptable. For receptor pharmacology, structure-activity relationship studies, or animal models where a 5% impurity could confound interpretation, specify ≥98% purity and verify the COA includes mass spectrometry confirmation and endotoxin testing. For investigator-initiated trials or work intended for FDA submission, use peptides synthesized in cGMP facilities with full batch documentation regardless of whether the supplier labels them 'real' or 'biotech' peptides.

Degradation rates depend on sequence composition, storage conditions, and reconstitution solvent. Peptides containing methionine, cysteine, tryptophan, or histidine are particularly susceptible to oxidation and should be stored under argon or nitrogen atmosphere after reconstitution. If you observe visible precipitation, color change, or loss of biological activity within the stated stability window, verify storage temperature with a calibrated thermometer. Most degradation is caused by temperature excursions, not inherent peptide instability. Aliquot reconstituted peptides into single-use volumes to avoid freeze-thaw cycles, which cause aggregation. If degradation persists under proper storage, the peptide may contain undisclosed impurities or the lyophilization process may have been incomplete, leaving residual moisture that accelerates hydrolysis.

Contact the supplier immediately and request the COA for the exact lot number printed on your vial. A legitimate supplier maintains batch records and can provide this documentation within 24–48 hours. If they cannot or will not provide a batch-specific COA, the peptide's purity and identity are unverified. Do not use it in experiments intended for publication or regulatory submission. Generic 'representative batch' COAs are insufficient because they don't document the specific peptide you received, only a previous batch that may or may not match your lot.

HPLC purity below 90% introduces significant experimental variability because the impurity fraction may include deletion sequences, acetylated side products, or related peptides with altered biological activity. If your research requires high-confidence results. Such as dose-response assays, receptor binding studies, or in vivo models. Request a replacement batch with ≥95% purity or switch to a supplier that consistently delivers higher purity. Lower-purity peptides are acceptable for preliminary screening or method development where some noise is tolerable, but not for mechanistic studies or clinical translation.